SNDX Syndax Pharmaceuticals Inc

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Commercial-stage biopharma focused on innovative cancer therapies with two FDA-approved drugs: Revuforj (menin inhibitor) and Niktimvo (CSF-1R antibody)
• • New FDA approval in Oct 2025 for Revuforj in relapsed/refractory AML with NPM1 mutation, expanding use beyond KMT2A translocation leukemia
• • Strategic emphasis on frontline combination trials for Revuforj to support label expansion and NCCN guideline inclusion for broader leukemia treatment
• • Launched Revuforj and Niktimvo in US in late 2024/early 2025; Revuforj Phase 3 EVOLVE-2 and REVEAL-ND pivotal trials initiated in 2025 targeting newly diagnosed AML
• • Initiated first clinical data program in 2026 for Revuforj in myelofibrosis and advancing axatilimab in idiopathic pulmonary fibrosis, representing novel disease areas

Risk Factors

• • Cybersecurity risk from IT system compromise with potential regulatory investigations and fines
• • Board audit committee oversees cybersecurity risk management with annual CFO reports on threats and mitigation
• • VP of IT with 25+ years experience responsible for cybersecurity strategy and budget approval
• • Escalation process includes CFO, CEO, and General Counsel for cybersecurity incident response
• • No specific regulatory, geopolitical, supply chain, competitive, or financial risks detailed in text

Management Discussion & Analysis

• • Revenue $172.4M in 2025 vs $23.7M in 2024; net product revenue Revuforj $124.8M vs $7.7M, collaboration revenue Niktimvo $42.4M vs $0
• • Net loss $285.4M in 2025 vs $318.8M in 2024; operating loss $273.1M vs $339.7M; operating margin approx. -158.5% vs -143.3% (losss as % of revenue)
• • Best performing segment: Revuforj product revenue $124.8M; worst: milestone/license revenue down $10.9M to $5.1M
• • Cash, equivalents & short-term investments $394.1M as of Dec 31, 2025; no explicit buybacks/dividends; increased SG&A by $58.8M primarily for commercial launch expenses
• • Forward outlook risk: high interest rates and recession risk may affect financing, inflation could raise operating costs, ongoing clinical and regulatory uncertainties

What are the latest SNDX SEC filings in 2026?

Syndax Pharmaceuticals Inc (SNDX) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on April 30, 2026, an 8-K current report on August 4, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did SNDX file its most recent 10-K annual report?

Syndax Pharmaceuticals Inc (SNDX) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view SNDX 10-Q quarterly reports?

Syndax Pharmaceuticals Inc (SNDX)'s most recent 10-Q quarterly report was filed on April 30, 2026. SignalX displays every SNDX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has SNDX filed recently?

Syndax Pharmaceuticals Inc (SNDX)'s most recent 8-K was filed on August 4, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find SNDX insider trading activity (Form 4)?

SignalX aggregates every SNDX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does SNDX file with the SEC?

Syndax Pharmaceuticals Inc (SNDX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new SNDX filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Syndax Pharmaceuticals Inc (SNDX).

What is SNDX's SEC CIK number?

Syndax Pharmaceuticals Inc (SNDX)'s SEC CIK (Central Index Key) number is 1395937. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1395937 to look up all SNDX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find SNDX return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Syndax Pharmaceuticals Inc (SNDX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.